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http://www.biomedcentral.com/1471-2199/15/1RESEARCH ARTICLE Open AccessMicroRNA miR-378 promotes BMP2-induced
osteogenic differentiation of mesenchymal
progenitor cells
Marlinda Hupkes1*, Ana M Sotoca1, José M Hendriks1, Everardus J van Zoelen1 and Koen J Dechering1,2,3Abstract
Background: MicroRNAs (miRNAs) are a family of small, non-coding single-stranded RNA molecules involved in
post-transcriptional regulation of gene expression. As such, they are believed to play a role in regulating the
step-wise changes in gene expression patterns that occur during cell fate specification of multipotent stem cells.
Here, we have studied whether terminal differentiation of C2C12 myoblasts is indeed controlled by lineage-specific
changes in miRNA expression.
Results: Using a previously generated RNA polymerase II (Pol-II) ChIP-on-chip dataset, we show differential Pol-II
occupancy at the promoter regions of six miRNAs during C2C12 myogenic versus BMP2-induced osteogenic
differentiation. Overexpression of one of these miRNAs, miR-378, enhances Alp activity, calcium deposition and
mRNA expression of osteogenic marker genes in the presence of BMP2.
Conclusions: Our results demonstrate a previously unknown role for miR-378 in promoting BMP2-induced
osteogenic differentiation.Background
The generation of distinct populations of terminally dif-
ferentiated, mature specialized cell types from multipo-
tent stem cells, via progenitor cells, is characterized by a
progressive restriction of differentiation potential that
involves a tightly controlled, coordinated activation and
repression of specific subsets of genes. This process de-
pends on the orchestrated action of key regulatory tran-
scription factors in combination with changes in epigenetic
modifications that regulate which regions in the genome
are accessible for transcription [1]. The more recently dis-
covered family of microRNAs (miRNAs) is thought to
provide an additional layer of gene control that integrates
with these transcriptional and epigenetic regulatory pro-
cesses to further modulate the final gene expression profile
of a specific cell type [2].
MicroRNAs (miRNAs) are a class of small, evolu-
tionarily conserved non-coding RNA molecules (~19-25* Correspondence: m.hupkes@science.ru.nl
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stated.nucleotides) involved in post-transcriptional gene silencing
and as such play important roles in diverse biological pro-
cesses such as developmental timing [3], insulin secretion
[4], apoptosis [5], oncogenesis [6] and organ development
[7,8]. MiRNAs are transcribed from the genome as long
primary transcripts (pri-miRNA) encoding one or more
miRNAs, which are processed in the nucleus by the so-
called ‘microprocessor’ complex consisting of DGCR8
(DiGeorge Syndrome Critical Region 8) and the ribonucle-
ase III (RNase III) enzyme DROSHA [9]. This liberates
the precursor-miRNA (pre-miRNA), a hairpin-type struc-
ture, which has a characteristic 3’ overhang of two nucleo-
tides and is subsequently exported from the nucleus by
Exportin-5, a RAN GTPase protein [10]. Inside the cyto-
plasm, the pre-miRNA hairpin loop is removed by a sec-
ond RNase III enzyme, DICER, yielding a ~22 nucleotide
long imperfect RNA duplex. This duplex contains two
potentially functional mature miRNAs termed the 5p
and 3p strands, referring to which end of the pre-
miRNA they are derived from [8]. One of these strandsLtd. This is an Open Access article distributed under the terms of the Creative
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complex (RISC), which guides the mature miRNA to its
target mRNA. In general, one strand is inserted into the
RISC complex at much higher efficiency than the other,
whereby the strand choice may be based on a variety of
factors including thermodynamic instability, strength of
the base-pairing and position of the stem-loop [11]. The
strand that is incorporated into RISC with lowest effi-
ciency is referred to with an asterisk (miRNA*) and, since
non-incorporated strands are thought to be degraded, is
less-abundant than its counterpart [12].
The RISC-incorporated miRNA regulates gene expres-
sion through sequence-specific interactions with its target
site, which is typically located within the 3’ untranslated
region (3’UTR) of an mRNA transcript. Animal miRNAs
usually exhibit only partial complementarity to their
mRNA targets, whereby nucleotides 2–8 at the 5’ end of
the miRNA, referred to as the ‘seed region’, are thought to
be the primary determinant of target specificity [11,13].
Interaction of the miRNA with its target mRNA can inter-
fere with protein translation and/or induce mRNA deg-
radation through a variety of different mechanisms [14],
thereby decreasing the protein output. The mechanism
and level of effect are thought to be influenced by the
degree of complementarity between the miRNA and its
mRNA target, the surrounding sequences in the target
3’UTR [12] and their relative abundance [15].
Estimated numbers of miRNA genes amount to nearly
1% of the number of predicted protein-coding genes in
the genome of higher eukaryotes, a percentage similar to
that of other large gene families with regulatory roles, such
as the homeodomain transcription factor family [11]. In
addition, miRNAs are estimated to target the expression
of approximately one-third of all mammalian genes [8].
Due to the imperfect complementarity between a miRNA
and its target, most miRNAs are predicted to be able to
bind to and regulate a large number of different mRNA
targets [2]. In addition, multiple different miRNAs can
synergistically target and control a single mRNA target
[2], providing the potential for complex regulatory net-
works. Many miRNAs studied so far are differentially
expressed during development and differentiation, sug-
gesting that each cell type might have its own unique
miRNA profile that could affect the utilization of thou-
sands of mRNAs and thus ‘micromanage’ the output of
the transcriptome [2,8]. Several studies have indeed pro-
vided examples of miRNAs that play a role in the regula-
tion of cellular differentiation, including hematopoietic
cell differentiation [16], adipogenesis [17], osteogenesis
[18] and myogenesis [12]. In addition, it has been shown
that expression of only three miRNAs (miR-200c, miR-302
and miR-369) is sufficient to induce pluripotency in mouse
cells, demonstrating that miRNAs can act as major deter-
minants of cell fate [19]. Since miRNAs have beendiscovered relatively recently, however, much still remains
to be learned about their role in cellular programming, in-
cluding the identification and detailed analysis of their
targets.
In the present study, we took advantage of the robust
and homogeneous differentiation characteristics of the
mouse C2C12 myoblast cell line to investigate whether
lineage-specific changes in miRNA expression might
underlie their terminal differentiation. C2C12 cells were
originally derived from regenerating muscle tissue [20]
and are considered to represent the transit amplifying
progenitor population that is derived from muscle satel-
lite stem cells [21]. When cultured under low-serum
conditions, C2C12 cells terminally differentiate and fuse
into multi-nucleated myotubes upon reaching confluence,
which is preceded by upregulation of the key myogenic
transcription factors Myod1 and Myog. However, treat-
ment of C2C12 cells with bone morphogenetic protein
(BMP) 2 induces these cells to differentiate into osteo-
blasts, which involves the upregulation of key osteogenic
transcription factors Dlx5, Sp7 and Runx2 [22-24], subse-
quently leading to the expression of late osteoblast marker
genes, such as Alpl and Bglap [25,26]. These character-
istics make C2C12 progenitor cells an excellent model
system to study the molecular mechanisms that underlie
cell-fate specification and terminal differentiation. Using a
previously generated RNA polymerase II (Pol-II) ChIP-on-
chip dataset [27], we show that several miRNAs have dif-
ferential Pol-II occupancy during C2C12 myogenic versus
osteogenic differentiation and that overexpression of one
of these miRNAs, miR-378, promotes BMP2-induced
osteogenic differentiation of C2C12 cells.
Results
C2C12 lineage-specific miRNA expression
To identify miRNAs that are differentially expressed
during C2C12 myogenic versus BMP2-induced osteo-
genic differentiation, and thereby might play a role in
lineage restriction, we made use of our previously gen-
erated Pol-II ChIP-on-chip dataset [27]. This dataset
contains Pol-II occupancy data for undifferentiated
C2C12 cells (d0) and cells treated with (osteogenesis) or
without (myogenesis) BMP2 for 1, 3 and 6 days, whereby
changes in Pol-II occupancy are considered to reflect
changes in transcriptional activity. Since miRNA genes are
usually also regulated by Pol-II promoters [28], this data-
set formed a good starting point to search for lineage-
specific miRNA expression profiles. Our selection criteria
(see Methods) thus led to the identification of 6 miRNA
genes, namely miR-21, miR-34b/c, miR-99b, miR-365-2,
miR-378 and miR-675, located in the vicinity of enriched
regions with differential Pol-II occupancy profiles during
myogenic versus osteogenic differentiation within our
dataset (Figure 1A).
Figure 1 C2C12 lineage-specific miRNA expression. C2C12 cells were treated with (diamonds) or without (circles) 300 ng/ml BMP2 for 6 days,
during which chromatin and RNA were harvested in parallel at d0, d1, d3 and d6. A) Pol-II enrichment [27] at regions associated with miRNA
genes miR-21 (RefSeq Accession NR_029738; enriched region from −1492 to +1661 bp), miR-34b/c (RefSeq Accessions NR_029655 and
NR_029654; enriched regions from −287 to +236 bp (miR-34b) and −822 to −299 bp (miR-34c)), miR-99b (RefSeq Accession NR_029536; enriched
region from −1113 to −399 bp), miR-365-2 (RefSeq Accession NR_029959; enriched region from +187 to +1282 bp), miR-378 (RefSeq Accession
NR_029879.1; enriched region from −2068 to −130 bp) and miR-675 (RefSeq Accession NR_030416.1; enriched region from −1055 to −235 bp) as
determined by Pol-II ChIP-on-chip analysis of single biological samples [27]. B) Mature miRNA levels of miR-365 (3p) and miR-378 (3p) as
determined by real-time PCR and expressed as a percentage of the control small, non-coding RNA snoRNA202. The mean values +/− SD from
duplicate measurements are shown for all data points.
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natively be associated to other surrounding (predicted)
genes, we subsequently validated whether the identified
Pol-II occupancy profiles correspond to the actual expres-
sion profile of two of these miRNAs, miR-365 and miR-
378, by quantitative PCR analysis of the mature miRNAs
(Figure 1B). For miR-365, the higher levels of Pol-II occu-
pancy on the associated enriched region during myogen-
esis versus osteogenesis is reflected by higher levels of
mature miRNA expression. While Pol-II occupancy ap-
pears to be specifically downregulated during osteogenesis
and does not change during myogenesis, however, mature
miR-365 levels do not change during osteogenesis and are
upregulated during myogenesis. For miR-378, the asso-
ciated Pol-II occupancy profile and the mature miRNA
expression pattern are very similar. These results confirm
a lineage-specific difference in the expression of both
miR-365 and miR-378. Given the high expression levels
of mature miR-378 relative to miR-365, we subsequently
focused on this miRNA to further investigate its potential
role in C2C12 lineage-specific differentiation.Effect of miR-378 overexpression on genome-wide mRNA
expression levels
To gain more understanding of the role and putative target
of miR-378 in C2C12 differentiation, we first created a sta-
bly transduced C2C12 cell line overexpressing miR-378
(C2C12-pMirn378) and a control cell line transduced with
the parent vector (C2C12-pMirn0). We subsequently exam-
ined the effect of miR-378 overexpression on gene expres-
sion levels during C2C12 lineage-specific differentiation by
means of genome-wide mRNA profiling of undifferentiated
(d0) C2C12-pMirn378 and control C2C12-pMirn0 cells
and of both cell lines treated with or without BMP2 for 3
and 6 days.
We first explored changes in gene expression levels dur-
ing differentiation of the control C2C12-pMirn0 cells.
Comparison of expression levels in differentiating cells (d3
and d6 time points) versus undifferentiated (d0) cells in
this control group revealed a significant upregulation of
4521 probes during C2C12-pMirn0 treatment without
BMP2. Functional gene annotation of this set of probes
according to Gene Ontology (GO: biological processes
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terms related to muscle development (including for ex-
ample ‘muscle organ development’, ‘striated muscle cell
development’, ‘muscle contraction’ and ‘muscle cell devel-
opment’; data not shown), consistent with an upregulation
of the muscle transcription program under these culture
conditions. This is illustrated by the expression profiles of
several myogenic marker genes in our control C2C12-
pMirn0 cells (Additional file 1A).
Similarly, we observed a significant upregulation of 4664
probes during C2C12-pMirn0 treatment with BMP2 (d3
and d6 time points) as compared to undifferentiated (d0)
cells in the control group. Functional gene annotation
of these probes according to GO (biological processes)
revealed significant enrichment of GO terms related to
bone development (including ‘skeletal system development’,
‘bone development’, ‘extracellular matrix organization’ and
‘ossification’, ‘skeletal system morphogenesis’, ‘osteoblast
differentiation’, ‘bone mineralization’; data not shown),
consistent with the expected osteogenesis-inducing effect
of BMP2 on our control C2C12-pMirn0 cells. The expres-
sion profiles of several osteogenic marker genes are pre-
sented in Additional file 1B.
Finally, control C2C12-pMirn0 cultures treated both
with and without BMP2 showed a clear cell cycle with-
drawal signature as common functional gene annotation
of the sets of probes significantly downregulated during
myogenic (5396 probes) and osteogenic (4550 probes) dif-
ferentiation. To illustrate, the expression profiles of several
cell-cycle regulators are shown in Additional file 1C.
We thus conclude that treatment of our control C2C12-
pMirn0 cells with and without BMP2 had induced the
expected changes in transcription patterns corresponding
to osteogenic and myogenic differentiation, respectively.
We next examined the effect of miR-378 overexpression
on these gene expression profiles. MiR-378 is expressed
approximately 11-fold higher in C2C12-pMirn378 cells
than in C2C12-pMirn0 cells at the d0 time point
(Figure 2A). Similar to C2C12-pMirn0 cells, miR-378
expression increases during myogenic differentiation
of C2C12-pMirn378 cells (Figure 2A). While miR-378
levels remain higher in C2C12-pMirn378 versus C2C12-
pMirn0 cells during myogenesis, the fold overexpression
decreases to approximately 3-fold at d3 and 2-fold at
d6 (Figure 2A). The fold overexpression of miR-378 in
C2C12-pMirn378 versus C2C12-pMirn0 cells also de-
creases to approximately 8-fold at d3 and 3-fold at d6
during BMP2-induced osteogenesis (Figure 2A).
Gene expression levels in C2C12-pMirn378 cells were
compared to those in control C2C12-pMirn0 cells for
each time point during each treatment separately. The
Venn diagrams in Figure 2B-C, Figure 3A and Figure 4A
demonstrate the number of probes found to be signifi-
cantly higher- or lower expressed in the C2C12-pMirn378cells versus C2C12-pMirn0 cells at each indicated time
point during myogenesis (Figure 2B-C) and osteogenesis
(Figures 3A and 4A). We subsequently focused on the sets
of probes that are consistently expressed at either higher
or lower levels at at least two consecutive time points dur-
ing differentiation.
The Venn diagram in Figure 2C shows that during myo-
genic differentiation hardly any probes are consistently
higher expressed in C2C12-pMirn378 cells than in the
C2C12-pMirn0 cells. However, we did observe a signifi-
cantly lower expression of 53 probes at two or more con-
secutive time points (Figure 2B). GO-analysis of this set of
probes (Figure 2D) revealed a significant enrichment of
GO terms associated with various alternative differenti-
ation pathways, including osteogenesis, blood vessel devel-
opment, neuron differentiation and cartilage development.
Most of these genes are, however, upregulated during
(both C2C12-pMirn378 and C2C12-pMirn0) myogenic
differentiation, so they do not appear to be specific for a
particular lineage. We did not observe any significant dif-
ferences between C2C12-pMirn378 and C2C12-pMirn0
cells in the expression of muscle marker genes, such as for
example the myogenic transcription factors Myog and
Mef2c, Ckm, Chrng and the sarcomeric proteins Actn3 and
Tnnc2 during myogenesis (Figure 2E), suggesting that
miR-378 overexpression does not have an effect on C2C12
muscle differentiation.
Compared to myogenesis, many more probes are dif-
ferentially expressed in C2C12-pMirn378 cells versus
C2C12-pMirn0 cells during osteogenic differentiation
(Figure 3A and Figure 4A). We observed a consistent (at
at least two consecutive time points) lower expression of
253 probes (Figure 3A) and higher expression of 286
probes (Figure 4A) in the C2C12-pMirn378 cells. GO-
analysis showed that the set of lower expressed probes
was significantly enriched for numerous GO terms asso-
ciated with muscle differentiation (including for example
‘striated muscle development’, ‘muscle tissue develop-
ment’ and ‘muscle organ development’: Figure 3B), and
includes genes such as the myogenic transcription fac-
tor Myog and the sarcomeric proteins Tnnt2 and Actc1.
These genes, which are upregulated during (both
C2C12-pMirn378 and C2C12-pMirn0) myogenesis, are
downregulated during BMP2-induced osteogenesis of
C2C12-pMirn0 cells, which is further enhanced in C2C12-
pMirn378 cells (Figure 3C). Besides terms associated with
muscle differentiation, GO-analysis also revealed significant
enrichment of GO terms associated with Wnt signaling
(‘Wnt receptor signaling pathway’ and ‘Wnt receptor sig-
naling pathway through beta-catenin’), which include
genes for the Wnt proteinsWnt5a andWnt10a. In control
C2C12-pMirn0 cells, Wnt10a is upregulated specifically
during myogenesis, while Wnt5a is upregulated specific-
ally during BMP2-induced osteogenesis (Figure 3C).
Figure 2 Effect of miR-378 overexpression on C2C12 muscle transcription program. A) Mature miR-378 levels in C2C12-pMirn0 (light bars)
and C2C12-pMirn378 (dark bars) cells at indicated time points during treatment with or without 300 ng/ml BMP2. MiR-378 levels are expressed as
a percentage of the control small, non-coding RNA snoRNA202. Mean values +/− SD of three biological replicates, whereby each measurement
was made in duplicate, are shown. *p < 0.05 when compared to the C2C12-pMirn0 sample at the same time point and treatment. B-C) Venn
diagrams representing the number of probes on the microarray that are significantly lower (B) or higher (C) expressed in C2C12-pMirn378 cells
than in control C2C12-pMirn0 cells at each time point during differentiation in the absence of BMP2. D) Enriched (p < 0.01) GO terms within the
set of probes that are significantly lower expressed in C2C12-pMirn378 versus C2C12-pMirn0 cells at at least two consecutive time points during
differentiation in the absence of BMP2. E) mRNA expression profiles of the muscle transcription factors myogenin (Myog; 1419391_at) and
myocyte enhancer factor 2C (Mef2c; 1421027_a_at) and other muscle marker genes muscle creatine kinase (Ckm; 1417614_at), the acetylcholine
receptor subunit gamma (Chrng; 1449532_at) and the sarcomeric genes fast troponin C2 (Tnnc2; 1417464_at) and actinin alpha 3 (Actn3;
1418677_at) at indicated time points during differentiation of C2C12-pMirn0 (light bullets) and C2C12-pMirn378 (dark bullets) cells treated with
(squares) or without (circles) 300 ng/ml BMP2 as revealed from microarray analysis. Mean expression values +/− SD from triplicate microarray
experiments are shown for all data points. When the error bar is not visible, the SD falls within the printed data point. All SD values are, however,
listed in Additional file 2. AEV = average expression value; *significantly different expression in C2C12-pMirn378 compared to control C2C12-pMirn0
at the same time point and treatment.
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Figure 3 Effect of miR-378 overexpression on C2C12 bone transcription program: downregulation. A) Venn diagram representing the
number of probes on the microarray that are significantly (as defined in Methods) lower expressed in C2C12-pMirn378 cells than in control
C2C12-pMirn0 cells at each time point during differentiation in the presence of 300 ng/ml BMP2. B) Enriched (p < 0.01) GO terms (in biological
processes category) within the set of probes that are significantly lower expressed in C2C12-pMirn378 versus C2C12-pMirn0 cells at at least two
consecutive time points during differentiation in the presence of 300 ng/ml BMP2. C) Microarray profiles of representative genes that are expressed at
significantly lower levels in C2C12-pMirn378 cells than in C2C12-pMirn0 cells at at least two consecutive time points during differentiation in
the presence of BMP2 (light bullets: C2C12-pMirn0, dark bullets: C2C12-pMirn378, squares: treatment with BMP2, circles: treatment without
BMP2); Myog, troponin T2, cardiac (Tnnt2; 1418726_a_at), actin alpha cardiac muscle 1 (Actc1; 1415927_at), wingless-related MMTV integration
site 5a (Wnt5a; 1436791_at) and 10a (Wnt10a; 1460657_at). For Myog, Tnnt2 and Actc1, expression levels are only shown for cells treated with
BMP2. Mean expression values +/− SD from triplicate microarray experiments are shown for all data points. When the error bar is not visible,
the SD falls within the printed data point. All SD values are, however, listed in Additional file 2. AEV = average expression value; *significantly
different expression in C2C12-pMirn378 compared to control C2C12-pMirn0 at the same time point and treatment (see Methods for definition).
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are consistently expressed higher in C2C12-pMirn378
cells than in C2C12-pMirn0 cells during BMP2 treat-
ment revealed significant enrichment of GO terms re-
lated to bone differentiation (including ‘skeletal system
development’, ‘extracellular matrix organization’, ‘bone
development’ and ‘ossification’: Figure 4B), and includes
genes for the osteogenic transcription factors Sp7 and
Dlx5 and other osteogenic marker genes such as Alpl,
Vdr, Col1a1, Pdgfra, Fgfr3 and Kazald1 (Figure 4C). The
higher expression of osteogenic marker genes in C2C12-
pMirn378 cells versus control C2C12-pMirn0 cells sug-
gests that overexpression of miR-378 has a positive effect
on C2C12 BMP2-induced osteogenic differentiation.
Putative miR-378 target selection and validation
While our mRNA profiling analysis revealed that a large
number of genes are affected by miR-378 overexpression,
we expected the majority of these changes in expression
to be the result of indirect, downstream events following
the initial effect of miR-378 on its direct target(s). We
therefore set out next to identify direct miR-378 target
genes. Given the general effect of miR-378 overexpression
on osteogenesis, we hypothesized that miR-378 might
target signaling pathways involved in the initial activation
of the osteogenic transcription program. We therefore fo-
cused on genes that were downregulated by miR-378 over-
expression early during BMP2 treatment (i.e. at at least
the d0 and d3 time point) and had at least one predicted
miR-378 target site in their 3’UTR (see Methods). From
this group, we selected three candidate target genes that
are known to play a role in the regulation of osteoblast
differentiation: the Wnt signaling proteins Wnt5a and
Wnt10a and the BMP-inhibitor Grem1 (gremlin 1).
To determine whether these candidates are indeed dir-
ectly targeted by miR-378, we used an in vitro luciferase
reporter assay. Reporter constructs containing the 3’UTRs
of Wnt5a, Wnt10a and Grem1, as well as a positive con-
trol containing the miR-378 target sequence, fused to a lu-
ciferase reporter gene were co-transfected into HEK293
cells together with the miR-378 overexpression pMirn378or control plasmid pMirn0 to examine changes in lucifer-
ase activity (see Methods). Overexpression of miR-378 sig-
nificantly suppressed luciferase activity of the positive
control, but had no significant effect on the 3’UTR-lucifer-
ase reporter constructs (data not shown). Our selected
candidates therefore do not appear to be direct targets of
miR-378.
Effect of miR-378 overexpression on C2C12 differentiation
Finally, we examined the overall effect of miR-378 over-
expression on C2C12 myogenesis and osteogenesis by
means of biochemical assays for differentiation markers.
The effect on myogenic differentiation was assessed by
comparing creatine kinase (Ck) activity in C2C12-pMirn0
and C2C12-pMirn378 cells after treatment with DM in
the absence of BMP2 (Figure 5A). Consistent with the lack
of effect on myogenic marker gene expression, no signifi-
cant differences in Ck activity were observed between the
two cell lines, again indicating that overexpression of miR-
378 does not affect C2C12 myogenesis.
The effect of miR-378 overexpression on osteogen-
esis was assessed by comparing alkaline phosphatase
(Alp) activity in and calcium release by C2C12-pMirn0
and C2C12-pMirn378 cells after treatment with BMP2
(Figure 5B-C). The results demonstrate both an increase
in Alp activity and a significant enhancement of calcium
deposition by the C2C12-pMirn378 cells. In agreement
with the higher expression levels of osteogenic marker
genes observed in this cell-line, these results further in-
dicate that overexpression of miR-378 enhances C2C12
BMP2-induced osteogenesis.
Discussion
In this study we used a previously generated Pol-II ChIP-
on-chip dataset to identify miRNAs that are differentially
expressed during C2C12 myogenic versus osteogenic dif-
ferentiation and thus possibly play a role in lineage specifi-
cation. Overexpression of one of these miRNAs, miR-378,
had no apparent effect on myogenesis while enhancing
BMP2-induced osteogenesis, suggesting a positive role for
this miRNA in the osteogenic differentiation program.
Figure 4 Effect of miR-378 overexpression on C2C12 bone transcription program: upregulation. A) Venn diagram representing the
number of probes on the microarray that are significantly (as defined in Methods) higher expressed in C2C12-pMirn378 cells than in control
C2C12-pMirn0 cells at each time point during differentiation in the presence of 300 ng/ml BMP2. B) Enriched (p < 0.01) GO terms (in biological
processes category) within the set of probes that are significantly higher expressed in C2C12-pMirn378 versus C2C12-pMirn0 cells at at least two
consecutive time points during differentiation in the presence of 300 ng/ml BMP2. C) Microarray profiles of bone markers Sp7 transcription factor
7 (Sp7; 1418425_at), distal-less homeobox 5 (Dlx5; 1449863_a_at), alkaline phosphatase (Alpl; 1423611_at), vitamin D receptor (Vdr; 1418175_at),
collagen type I alpha 1 (Col1a1; 1423669_at), platelet derived growth factor receptor alpha polypeptide (Pdgfra; 1421917_at), fibroblast growth
factor receptor 3 (Fgfr3; 1421841_at) and Kazal-type serine peptidase inhibitor domain 1 (Kazald1; 1436528_at) at indicated time points during
differentiation of C2C12-pMirn0 (light bullets) and C2C12-pMirn378 (dark bullets) cells treated with (squares) or without (circles) 300 ng/ml BMP2
as revealed from microarray analysis. Mean expression values +/− SD from triplicate microarray experiments are shown for all data points. When
the error bar is not visible, the SD falls within the printed data point. All SD values are, however, listed in Additional file 2. AEV = average
expression value; *significantly different expression in C2C12-pMirn378 compared to control C2C12-pMirn0 at the same time point and treatment
(see Methods for definition).
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C2C12 myogenic differentiation corresponds well to other
reports demonstrating miR-378 upregulation during myo-
genesis and high levels of this miRNA in skeletal muscle
[29,30]. This upregulation of mature miR-378 matches an
increase in Pol-II occupancy at a region located within thefirst intron of the Ppargc1b gene, just upstream of the
miR-378 gene. This Pol-II enriched area lies adjacent to
an E-box containing Myod-binding region previously
shown to be important for miR-378 upregulation during
myogenesis [29]. Approximately a third of all miRNA
genes, including miR-378, lie within introns of protein-
Figure 5 Effect of miR-378 overexpression on C2C12 differentiation. A-C) Creatine kinase (A) and Alp (B) activity in and calcium deposition
(C) by C2C12-pMirn0 (light bars) and C2C12-pMirn378 (dark bars) cells after 6 (A-B) or 10 (C) days of culture in the presence or absence of
300 ng/ml BMP2. A) The mean values +/− SD of two biological replicates, whereby each measurement was made in duplicate, are shown. B) Mean
values +/− SD of three independent experiments with biological duplicates each. For each independent experiment, Alp activity values were
normalized to the average of the C2C12-pMirn0 samples treated with BMP2. C) Data shows calcium deposition in 24-well plates and is
representative of 2 independent experiments. Mean values +/− SD of two biological replicates in one experiment, whereby each measurement
was made in duplicate, are shown. *p < 0.05 when compared to the C2C12-pMirn0 sample with the same treatment. AU: arbitrary units.
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co-regulated with their host genes and subsequently
processed to mature miRNAs after splicing of the pre-
messenger RNAs [31]. However, the mRNA expression
profile of the miR-378 host gene, Ppargc1b, as assessed
by our microarray analysis, does not fully correspond to
the mature miR-378 expression profile; while miR-378
is upregulated during myogenesis, Ppargc1b mRNA
levels do not change (data not shown). Together with
the increase in Pol-II and Myod occupancy seen at sites
within the first Ppargc1b intron, this might suggest that
miR-378 is regulated independently from Ppargc1b and
transcribed as an independent transcript, an interesting
hypothesis that requires further study.
The upregulation of miR-378 specifically during C2C12
myogenic differentiation suggests a role for this miRNA in
this pathway. Indeed, a study by Gagan et al. has shown
that miR-378 promotes C2C12 myogenesis by targeting
Msc (musculin, also known as myogenic repressor; MyoR),
a repressor of myogenic differentiation that inhibits Myod
activity by binding to its co-activators or binding directly
to Myod target sequences [29]. In addition, miR-378 has
been shown to target mitogen-activated protein kinase 1
(Mapk1) and Bmp2, which are relevant to myoblast prolif-
eration and differentiation, respectively, in pigs [30]. Simi-
larly, miR-378 has also been shown to play a role in the
repression of cardiac hypertrophy by targeting Mapk1,
Igf1r (insulin-like growth factor 1 receptor), Grb2 (growth
factor receptor-bound protein 2) and Ksr1 (kinase sup-
pressor of ras 1), components of the MAP kinase path-
way, in rat cardiomyocytes [32]. In contrast, we did not
observe any significant effect of overexpression of miR-
378 on C2C12 myogenesis, as assessed by the expres-
sion of several myogenic marker genes and Ck activity.
The discrepancy with the work of Gagan et al. might be
attributed to a difference in levels of miR-378 overexpres-
sion resulting from the use of different overexpressionmethods (transient lipofectamine transfection versus our
stable lentiviral-transduced cell lines). Alternatively, since
the positive effects on myogenesis seen by Gagan et al.
were at early time points (day 1 and day 3), it is possible
that overexpression of miR-378 merely accelerates myo-
genesis and similar maximal levels have been reached by
both miR-378 overexpressing and control cells at the later
time points that we investigated (day 3 and day 6). Our
observation that miR-378 overexpression has no apparent
effect on myogenesis does not rule out that it plays a role
in this process; most likely, endogenous levels of this
miRNA are sufficient for its biological function, and over-
expression has no additional effect on myogenic markers.
It would, however, still be interesting to take a closer
look at the genes that are downregulated by miR-378
overexpression in undifferentiated myoblasts (day 0 time
point); genes that are downregulated during C2C12 myo-
genesis, and significantly downregulated by miR-378 over-
expression in myoblasts, such as for example (data not
shown) Fgf7 (fibroblast growth factor 7), Crlf1 (cytokine
receptor-like factor 1), Ereg (epiregulin) and Cck (chole-
cystokinin), are potential targets of this miRNA and inter-
esting candidates for further study on the role of miR-378
in myogenesis. Unfortunately, we did not observe a signifi-
cant effect of miR-378 overexpression on mRNA levels of
its published targets Msc, Mapk1, Igf1r, Grb2 and Ksr1
[29,30,32]. This does not contradict the findings in these
publications, since it is possible that miR-378 exerts its
effect on these targets at the level of protein translation
and not by inducing mRNA degradation (see below).
Besides its putative role in myogenesis, we clearly
demonstrate an effect of miR-378 on C2C12 bone differ-
entiation. Our observation that miR-378 overexpression
promotes C2C12 osteogenesis in the presence of BMP2,
as assessed by Alp activity, calcium deposition and expres-
sion of osteogenic marker genes, was surprising consider-
ing the lack of changes in its expression level during
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of miR-378 overexpression is limited only to BMP2-
treated cells, we believe that miR-378 on its own is not a
major determinant of the osteogenic cell fate, but more
likely plays a role in fine-tuning osteogenic gene expres-
sion within the BMP2-induced cellular environment.
A role for miR-378 in modulating osteogenic differ-
entiation has previously been described by Kahai et al.
in the context of a nephronectin (Npnt)-3’UTR over-
expressing MC3T3-E1 osteo-progenitor cell line [33].
Npnt is an extracellular matrix protein that, when
overexpressed, enhances MC3T3-E1 osteoblast differ-
entiation. Npnt secretion depends on its glycosylation
by glycosylation-associated enzymes including Galnt7
(UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 7). The 3’UTR of both
Npnt and Galnt7 contain a miR-378 binding site. Kahai
et al. demonstrated that, during late stages of MC3T3-
E1 development (in the presence of ascorbic acid, β-
glycerophosphate and dexamethasone), stable cell lines
overexpressing Npnt containing its 3’UTR (Npnt-3’UTR)
have a higher rate of osteoblast differentiation and bone
nodule formation than cell lines overexpressing Npnt
without its 3’UTR; this is further enhanced by co-
transfection with miR-378. Interestingly, co-transfection
of Npnt-3’UTR with miR-378 enhanced production of
Npnt and promoted Npnt glycosylation. It was sug-
gested that interaction of the Npnt 3’UTR with miR-378
sequestered this miRNA away from Galnt7, leading to
enhanced Galnt7 activity, a subsequent increase in Npnt
glycosylation and secretion and, as a result, a higher rate
of osteogenesis. In addition, it was proposed that binding
of miR-378 to the Npnt 3’UTR resulted in preventing
access of other miRNAs, thereby protecting the Npnt
mRNA from post-transcriptional regulation and resulting
in the observed increase in Npnt synthesis [33]. In line
with these findings, we observed significantly higher levels
of Npnt mRNA in our C2C12-pMirn378 versus control
cells after 6 days of osteogenic differentiation (data not
shown). It would therefore be interesting to determine
whether a similar Npnt/Galnt7 –mediated mechanism
might also play a role in the effect miR-378 overexpression
has on BMP2-induced C2C12 osteogenesis. However, the
positive effect of miR-378 overexpression on MC3T3-E1
osteoblast differentiation described by Kahai et al. was
only observed when co-transfected with Npnt-3’UTR and
only during later stages of development. In fact, stable
transfection of MC3T3-E1 cells with miR-378 alone actu-
ally inhibited osteogenesis [33]. This is in direct contrast
with our observation in BMP2-induced C2C12 cells and
indicates that the effect of miR-378 may depend on the
osteogenic model system used and/or the signaling path-
ways involved in inducing differentiation: for example, it is
conceivable that miR-378 acts specifically on the BMP2signaling pathway to positively reinforce the BMP2 effect
on our C2C12 model system, while this mechanism might
not play a role in the differentiation of MC3T3-E1 cells by
Kahai et al., which occurred in the absence of BMP2. Fur-
ther exploration of the mechanism underlying the positive
effect of miR-378 on our BMP2-induced C2C12 system
may help shed light on this issue.
We were as yet unable to identify the genes that are
directly targeted by miR-378 during BMP2-induced
C2C12 osteogenesis. Most effects seen in our mRNA
microarray analysis are likely to be secondary to the ini-
tial effect of miR-378, making it difficult to identify its
direct target(s). Given the overall positive effect of miR-
378 on the expression of osteogenic markers, and nega-
tive effect on myogenic markers, we expected the initial
targeting event to take place early during the differenti-
ation process. To identify direct miR-378 targets, we
therefore selected genes a) that were downregulated by
miR-378 overexpression early (day 0) and consistently
during osteogenesis, b) that contained a predicted miR-
378 target site in their 3’UTR and c) that were known to
play a role in the regulation of osteoblast differentiation.
This led to the selection of Grem1, Wnt5a and Wnt10a
as putative targets. Grem1 is a secreted glycoprotein
that binds BMP2 and prevents BMP2 signaling and ac-
tivity in cells of the osteoblast lineage [34]. Targeting of
Grem1 by miR-378 could thus increase the levels of
BMP2 available for inducing osteogenesis. Wnts are a
family of 19 secreted glycoproteins that activate their cell
surface receptors to induce specific intracellular signaling
cascades controlling gene expression and play a critical role
in embryonic development, postnatal development and
adult tissue homeostasis [35]. Wnt signaling regulates cellu-
lar processes including proliferation, differentiation, and
apoptosis through β-catenin-dependent canonical and β-
catenin-independent non-canonical pathways and has been
shown to play an important role in bone formation [36].
Wnt5a has been found to be the most dominant Wnt
expressed during osteogenesis of human mesenchymal
stem cells (hMSCs) both in vitro and in vivo [37] and
Wnt5a signaling has been shown to be important for
BMP2-mediated osteogenesis in MC3T3-E1 cells, though
the exact signaling pathways involved remain unclear [38].
Wnt10a has also been shown to stimulate osteogenesis
[39]. Given their important role in osteoblast formation, it
was interesting to determine whether these Wnts were in-
deed targeted by miR-378 and subsequently how this could
relate to the observed increase in osteogenic differentiation.
However, our luciferase-reporter assay demonstrated that
miR-378 did not directly target the 3’UTR of any of these
selected candidates and further work is thus required to
identify the mechanism by which miR-378 exerts its effect.
The imperfect complementarity that may exist between
a miRNA and its target, the possibility for combinatorial
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to observe an effect, and the various mechanisms by which
miRNAs may act, pose a great challenge common to all
studies of miRNA function. In our approach we assumed
that miR-378 exerts its effect by mRNA destabilization
and/or degradation, resulting in a decrease in mRNA
levels of its target(s). It is possible, however, for a miRNA
to have only very subtle effects on (multiple) targets that
cannot be observed as a change in mRNA levels of its dir-
ect targets, or to affect protein translation without affect-
ing mRNA levels [14,40]. In addition, miRNAs have been
shown to be able to affect mRNA levels of their target
genes via alternative mechanisms than binding to their
3’UTR, which would not be detected using a luciferase-
3’UTR reporter assay. For instance, it has been shown that
miRNAs can affect gene transcription by inducing histone
modifications at target promoter sites [41]. Interestingly, a
study by Gerin et al. has shown that miR-378 can specific-
ally increase the transcriptional activity of Cebpa and
Cebpb (CCAAT/enhancer binding protein, alpha and
beta) on adipocyte gene promoters, though it could not be
excluded that this was an indirect effect through e.g. in-
hibition of a co-repressor [42]. Given the role of Cebpb in
synergizing with Runx2 to regulate bone-specific gene ex-
pression [43], it would be very interesting to investigate
whether a similar mechanism underlies the effect of miR-
378 on BMP2-induced osteogenesis.
So far, we have attributed the effects seen in C2C12 cells
transduced with the miR-378 precursor expression con-
struct to mature miR-378, the 3p strand of the precursor
miRNA. However, it should be noted that these cells also
overexpress miR-378*, the less-abundant 5p strand. Al-
though present at 10–30 times lower levels than miR-378
(data not shown), it cannot be excluded that the effects
seen are (in part) the result of miR-378* overexpression,
and it would thus be interesting to also search for putative
miR-378* targets within the group of affected genes.
In this study, we used our previous Pol-II ChIP-on-
chip dataset to identify lineage-specific miRNA expres-
sion. Since the probes on the arrays used for this dataset
were restricted to promoter sequences of protein coding
genes, the results of this approach do not represent the
full picture of Pol-II occupancy at all miRNA gene pro-
moters in the genome. This could explain why several
miRNAs known to be specifically upregulated during
myogenesis, the so-called myomiRs (miR-1/206 and
miR-133 families) [12], were not identified. However, our
approach did provide a first means to identify several
miRNAs with differential Pol-II occupancy during myo-
genic versus osteogenic differentiation. Most of these
miRNAs, including miR-21, miR-34b/c, miR-99b, miR-365
and miR-675, have an as yet unknown role in these differ-
entiation pathways and are thus attractive candidates for
further investigation.Conclusions
In the present study we have identified a list of miRNAs
that potentially play a role in C2C12 lineage specification
and demonstrated a previously unknown role for miR-378
in enhancing BMP2-induced osteogenic differentiation.
Future studies will focus on further exploring the precise
function of these miRNAs during cellular differentiation,
including the challenging task of identifying their targets
and mechanisms of action.
Methods
Cell culture and treatment
Murine C2C12 myoblasts (as well as C2C12-derived stable
cell lines: see below) and Human Embryonic Kidney
(HEK) 293 cells (American Type Culture Collection,
Manassas, VA) were maintained at subconfluent dens-
ities in DMEM (Invitrogen, Carlsbad, CA), supplemented
with 10% newborn calf serum (NCS; Thermo Fisher Sci-
entific, Waltham, MA), antibiotics (100 U/ml penicillin,
100 μg/ml streptomycin: Sigma-Aldrich, St. Louis, MO),
and 2 mM L-glutamine (Invitrogen), further designated
as growth medium (GM), at 37°C in a humidified atmos-
phere containing 7.5% CO2. To study C2C12 differenti-
ation, cells were plated at 2.5 × 104 cells per cm2 in GM
and grown for 24 hours to sub-confluence. Subsequently,
medium was replaced by DMEM containing 5% NCS (re-
ferred to as differentiation medium (DM)) in the presence
or absence of 300 ng/ml recombinant human bone mor-
phogenetic protein 2 (BMP2; R&D Systems, Minneapolis,
MN). For calcium deposition studies, 0.2 mM ascorbate
and 10 mM β-glycerophosphate were added to the DM.
Medium was replaced every 3–4 days.
Pol-II ChIP-on-chip and selection of differentially enriched
microRNA genes
Generation of the RNA polymerase II (Pol-II) ChIP-on-
chip dataset used in this study has been described in
Hupkes et al. [27]. Enriched regions within 500 base pairs
(bp) upstream from a miRNA transcription start site (TSS),
within the miRNA gene, or up to 500 bp downstream from
the gene end were assigned to that associated miRNA.
MiRNA-associated active regions with an absolute average
log2 fold > 0.4 of untreated over BMP2-treated Pol-II en-
richment values at each time point were selected as differ-
entially expressed during myogenic versus BMP2-induced
osteogenic C2C12 differentiation.
RNA isolation and miRNA real-time polymerase chain
reaction (PCR)
RNA (including miRNA) was extracted using TRIzol®
according to the manufacturer’s instructions (Invitrogen).
RNA was precipitated with isopropanol and, after air-
drying, dissolved in DEPC-treated H2O. Total RNA
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at 260 nm.
The TaqMan® miRNA Reverse Transcription Kit (Applied
Biosystems, Carlsbad, CA), including TaqMan® stem-loop
primers miR-378 and miR-365 (cat. # 4427975_002243
and 4427975_001020, respectively; TaqMan® miRNA
Assays (Applied Biosystems)) and snoRNA202 (cat. #
4427975_001232; TaqMan® Small RNA Control Assays
(Applied Biosystems)) were used for reverse transcrip-
tion (RT) of miR-378 (3p), miR-365 (3p) and the small,
non-coding control RNA snoRNA202 from 100 ng of
total RNA each, according to the manufacturer’s protocol.
TaqMan® PCR primers and probes for miR-378, miR-
365 and snoRNA202, included in the above-mentioned
TaqMan® miRNA and small RNA Control assays, together
with the TaqMan® Universal PCR Master Mix II, no uracil
N-glycosylase (UNG) (Applied Biosystems) were subse-
quently used for quantitative PCR analysis, also according
to the manufacturer’s instructions. MiR-378 and miR-365
expression levels were expressed as a percentage of the
control small, non-coding RNA snoRNA202.
Expression constructs
The lentivector-based miR-378 precursor expression con-
struct PMIRH378PA-1 (referred to as ‘pMirn378’) and its
parent lentivector pCDH-CMV-MCS-EF1-copGFP (re-
ferred to as ‘pMirn0’) were purchased from System Biosci-
ences (Mountain View, CA). Both vectors contain an
expression module for the copGFP fluorescent marker
gene to enable monitoring of cells positive for transfection
and transduction. MiTarget™ 3’UTR miRNA target clones
were purchased from GeneCopoeia (Rockville, MD) and
consisted of the Grem1, Wnt5a or Wnt10a (accession
numbers NM_011824.3, NM_009524.2 and NM_009518.1
respectively) 3’UTR sequence, the miR-378 target se-
quence (5’-CCTTCTGACTCCAAGTCCAGT-3’; positive
control) or no additional sequence (negative control)
inserted in the pEZX-MT01 vector downstream of the
firefly luciferase reporter gene (constructs are referred to
as Grem1-luc, Wnt5a-luc, Wnt10a-luc, Pos-luc and Neg-
luc, respectively). The firefly luciferase gene, driven by an
SV40 promoter, resulted in the transcription of a chimeric
transcript consisting of luciferase and the inserted target
sequence. The pEZX-MT01 vector also contained the
Renilla luciferase gene under the control of a CMV pro-
moter to allow dual analysis of firefly and Renilla lucif-
erase activities in individual samples. Firefly luciferase
activity was thus normalized to account for potential
differences in transfection efficiencies between different
samples.
Stable C2C12-pMirn cell lines
Lentiviruses were produced from pMirn378 and pMirn0
as described previously [44]. For infection, C2C12 cellswere initially seeded in a 24-wells plate in GM at a density
of 3.0 × 103 cells per well. The next day, cells were in-
fected for 48 hours with 800 ng of virus in GM containing
8 μg/ml of polybrene, whereby the infection medium was
refreshed after 24 hours. The cells were then washed twice
with GM and maintained in GM for another 24 hours.
Subsequently, cells were transferred to T75 flasks and
maintained in GM until a confluency of approximately
60% was reached. Finally, copGFP-positive cells were
sorted by FACS, resulting in the stably transduced cell
lines C2C12-pMirn0 and C2C12-pMirn378.Microarray processing and identification of significantly
regulated genes
For mRNA expression profiling analysis, total RNA samples
were purified using the RNeasy Mini Kit (Qiagen, Venlo,
the Netherlands), according to the manufacturer’s RNA
cleanup protocol. Quality of RNA samples was evaluated
by capillary electrophoresis on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). In total, 30
RNA samples were obtained from triplicate experiments
of C2C12-pMirn0 or C2C12-pMirn378 cells cultured
for 0, 3 or 6 days in DM with or without 300 ng/ml
BMP2. Following purification, 200 ng of total RNA were
amplified, labeled, and fragmented using the GeneChip
3’ IVT Express Kit (Affymetrix, Santa Clara, CA) ac-
cording to the manufacturer’s instructions. Fragmented
amplified RNA (10 μg) was subsequently applied to the
GeneChip Mouse Genome 430 2.0 array (Affymetrix)
and hybridized for 16 hours at 45°C at 60 rpm in a Gen-
eChip Hybridization Oven 640 (Affymetrix). Following
hybridization, the arrays were washed and stained with
a GeneChip Fluidics Station 450 (Affymetrix) using the
Affymetrix Hybridization Wash Stain (HWS) kit. The
arrays were laser scanned with a GeneChip Scanner
3000 7G (Affymetrix). Data was saved as raw image file
and quantified using Affymetrix GeneChip Command
Console v 1.0 (Affymetrix). These data were imported to R
2.4.1 using the Bioconductor (www.bioconductor.org)
Affymetrix package. The model-based Robust Multiarray
Average (RMA) algorithm was used to generate the probe
set summary based on the full annotation on gene level
and normalization was done according to the quantile
method. To identify genes that are differentially expressed
in C2C12-pMirn378 versus C2C12-pMirn0 samples, ex-
pression ratios were calculated for each time point and
treatment using the Limma algorithm in R, applying mod-
erated t-tests. A similar approach was taken to identify
genes that are up- or downregulated during differentiation
of C2C12-pMirn0 cells, whereby expression ratios were
calculated for each time point during each treatment ver-
sus the d0 base line value. To correct for multiple hypoth-
esis testing, the q value [45] was calculated for each p
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significance of the corresponding ratio.
Genes with a q value < 0.005 and an absolute log2
expression ratio between C2C12-pMirn378 and C2C12-
pMirn0 > 0.6 were considered to be significantly differ-
entially expressed at the corresponding time point and
treatment. Genes with a q value < 0.005 for the d6 vs d0
time point and an average log2 expression ratio of the
d3 vs d0 and d6 vs d0 time points < −0.6 or > 0.6 for the
same treatment were considered to be significantly down-
or upregulated, respectively, during that particular treat-
ment. Results are listed in Additional file 2. In addition,
raw and processed microarray data were submitted to the
U.S. National Center for Biotechnology Information Gene
Expression Omnibus (GEO) database (GSE51883). The
Web-based platform DAVID Bioinformatics Resources
[46] was used to identify enriched Gene Ontology (GO)
terms of the biological process category [47] in the sets of
significantly differentially expressed genes relative to all
probes represented on the array, whereby a p value < 0.01
was considered a significant enrichment.
Target prediction
TargetScan version 4.0, PITA, DIANA, PicTar, FINDTAR3
and Miranda databases were used to identify potential
miR-378 target sites in genes that were downregulated in
C2C12-pMirn378 cells as compared to C2C12-pMirn0
cells.
Transfections and luciferase reporter assays
HEK293 cells were seeded in 24-well plates in GM and
medium was refreshed after 24 hours. One hour prior to
transfection, medium was replaced by GM lacking antibi-
otics. 3’UTR miRNA target clones (0.4 μg) were subse-
quently co-transfected with pMirn0 or pMirn378 (0.4 μg)
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. After 5 hours of incubation
with transfection reagents, medium was replaced by GM.
Twenty-four hours later, firefly and Renilla luciferase ac-
tivities were measured from the same samples using the
LucPair™ miR Duo-Luciferase Assay Kit according to the
manufacturer’s instructions (Genecopoeia). Firefly lucifer-
ase activity was then normalized for transfection efficiency
using the Renilla luciferase activity in the same sample.
Normalized luciferase values are presented as percentage
of the control samples co-transfected with the Neg-luc
vector.
Creatine kinase assay
Creatine kinase (Ck) enzymatic activity was measured in
cell lysates using the EnzyChrom™ Creatine Kinase
Assay Kit (ECPK-100, BioAssay Systems, Hayward, CA)
according to the manufacturer’s protocol. Cell lysates
were obtained from cells seeded in 48-well plates: cellswere washed twice with PBS, lysed by incubation in
50 μl lysis buffer (Promega, Madison, WI) on ice for 10
minutes, scraped loose and spun down to remove cellular
debris. Supernatant was then collected and diluted 2.5
times in H2O, of which 10 μl was used for each Ck meas-
urement. Results of the Ck assay were normalized for pro-
tein content, as measured using the Bio-Rad Protein assay
(Bio-Rad, Hercules, CA) according to the manufacturer’s
protocol (“Microassay Procedure for Microtiter Plates”)
and thus expressed as ‘arbitrary units (AU)’. Samples were
diluted such that absorbance at 595 nm for each sample
fell within the linear range of a bovine serum albumin
(BSA) standard curve.
Alkaline phosphatase and mineralization assays
Alkaline phosphatase (Alp) enzymatic activity was mea-
sured as described previously [48] and normalized for
neutral red staining to correct for potential differences
in cell number [49].
Calcium deposition in the extracellular matrix (calcium
release) was measured as described by Piek et al. [44].
Statistical analysis
For miRNA real-time PCR analysis, Ck, Alp, calcium
and luciferase assays, Student’s 2-tailed t test was used
to compare miR-378-overexpressing samples with their
controls whereby a difference with p < 0.05 was considered
significant.
Availability of supporting data
The raw and processed microarray data sets supporting




Additional file 1: Figure S1. Microarray expression profiles of control
C2C12-pMirn0 cells. mRNA expression profiles of A) the muscle transcription
factors myogenin (Myog; 1419391_at) and myocyte enhancer factor 2C
(Mef2c; 1421027_a_at) and other muscle marker genes muscle creatine
kinase (Ckm; 1417614_at), the acetylcholine receptor subunit gamma
(Chrng; 1449532_at) and the sarcomeric genes fast troponin C2 (Tnnc2;
1417464_at) and actinin alpha 3 (Actn3; 1418677_at), B) the osteogenic
transcription factors Sp7 transcription factor 7 (Sp7; 1418425_at), distal-less
homeobox 5 (Dlx5; 1449863_a_at) and runt-related transcription factor 2
(Runx2; 1424704_at), and other osteogenic marker genes alkaline
phosphatase (Alpl; 1423611_at), bone gamma-carboxyglutamate (gla)
protein (Bglap; 1449880_s_at) and vitamin D receptor (Vdr; 1418175_at)
and C) the cell-cycle regulators cyclins A2 (Ccna2; 1417910_at) and B1
(Ccnb1; 1419943_s_at), cell division cycle 7 (Cdc7; 1426002_a_at) and 20
(Cdc20; 1416664_at) and the cyclin-dependent kinases 1 (Cdk1;
1448314_at) and 4 (Cdk4; 1422441_x_at) at indicated time points during
differentiation of C2C12-pMirn0 cells treated with (diamonds) or without
(circles) 300 ng/ml BMP2 as revealed from microarray analysis. Mean
expression values +/− SD from triplicate microarray experiments are
shown for all data points. When the error bar is not visible, the SD falls
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Additional file 2. AEV = average expression value.
Additional file 2: Table S1. Results of mRNA expression profiling. Gene
expression profiling results, listing normalized values in C2C12-pMirn0
and C2C12-pMirn378 cells after 0 (d0), 3 (d3) and 6 (d6) days of treatment
with or without 300 ng/ml BMP2 as average and standard deviation of
three biological replicates, including q values for indicated combinations.
Genes that are significantly up- or downregulated during myogenic
(column AF) and osteogenic (column AG) differentiation of C2C12-pMirn0
control cells are indicated with ‘SU’ and ‘SD’ , respectively, in the appropriate
columns. Genes that are significantly up (SU)- or downregulated (SD) in
C2C12-pMirn378 cells as compared to C2C12-pMirn0 cells during
myogenesis (column AH (SD) and AI (SU)) or osteogenesis (column AJ
(SD) and AK (SU)) are grouped into 7 groups; 1-significant difference
only on d0; 2-significant difference only on d3; 3-significant difference
only on d6; 4-significant difference on d0 and d3; 5-significant difference on
d3 and d6; 6-significant difference on d0 and d6; 7-significant difference on
d0, d3 and d6.
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